Skip to content

Medical Affairs

Intelligence Hub

Overview

Home
My Work
Command Center

Plan & execute

Medical Plans
Launch Readiness
Budget & Resources
Risks & Decisions

Field & science

Engagements
Insights
Evidence Generation

Communicate

Publications
Congresses
Medical Information

Govern

Reports
Data Quality
Administration

Helixor Therapeutics

Sample data · FY2026

Scope·4 products·FY2026

HODr. Helen OkaforGlobal Head of Medical Affairs

EngagementsENG-0057

Payer / HTA meeting · Dr. Chloé Dubois

09 Aug 2026 · In person · Dr. Chloé Dubois, UCLH · MSL James Whitfield · Vantrexa

ReviewedVeeva CRMENG-0057MI request

Capture insight from this engagement

Location: Hospital Clínic Barcelona
Therapeutic area: Oncology
Country: United Kingdom
Stakeholder tier: Tier 3
Strategic objective: Not linked
Initiative: Not linked
MSL: JWJames WhitfieldSenior MSL, Oncology (US East)
Product: Vantrexa (vantrelimab)

Topics discussed

Sequencing after progression
Duration of response

Scientific content used

VOYAGE-1 pivotal data summary
PD-L1 testing pathway infographic

Questions raised

How should grade 2 infusion reactions be managed without steroids?

Notes

Payer / HTA meeting with radiation oncologist at Hospital Clínic Barcelona. Discussed sequencing after progression, duration of response.

Insights captured (0)

Capture insight

No insights captured from this engagement.

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

Invite to advisory board

0 of 1 complete

Quality ratings

1–5, rated at review

Scientific relevance: 3
Strategic relevance: 4
Depth of exchange: 2
Actionability: 3

Data lineage

Source system: Veeva CRM
Sync: Veeva CRM · synced 2026-09-15 08:00 UTC
System of record: Veeva CRM
Record id: ENG-0057

Audit history (0)

All create, update and approval events for this record

No audit events in sample data